Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 21, Issue 12, Pages 2324-2332
Publisher
Oxford University Press (OUP)
Online
2010-05-25
DOI
10.1093/annonc/mdq204
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy for Lung Cancer
- (2010) Penelope A. Bradbury et al. Journal of Thoracic Oncology
- Alternating XELFOX and XELFIRI in Patients With Metastatic Colorectal Cancer
- (2009) Francesco Recchia et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
- (2009) D. M. Jackman et al. CLINICAL CANCER RESEARCH
- Emerging therapies in castrate-resistant prostate cancer
- (2009) Kiran Lassi et al. CURRENT OPINION IN ONCOLOGY
- Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
- (2009) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials
- (2009) Suman Bhattacharya et al. JOURNAL OF CLINICAL ONCOLOGY
- Issues in Using Progression-Free Survival When Evaluating Oncology Products
- (2009) Thomas R. Fleming et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
- (2009) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Ixabepilone: targeting III-tubulin expression in taxane-resistant malignancies
- (2009) C. Dumontet et al. MOLECULAR CANCER THERAPEUTICS
- FDA Review of a Panitumumab (VectibixTM) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer
- (2009) R. M. Giusti et al. ONCOLOGIST
- Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
- (2009) A. Morabito et al. ONCOLOGIST
- Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
- (2008) E. D. Saad et al. ANNALS OF ONCOLOGY
- Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer
- (2008) Malik Berhoune et al. ANNALS OF PHARMACOTHERAPY
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer
- (2008) B Sherrill et al. BRITISH JOURNAL OF CANCER
- Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)
- (2008) Valentina Guarneri et al. Clinical Breast Cancer
- Management of Unresectable Stage III Non–Small-Cell Lung Cancer with Combined-Modality Therapy: A Review of the Current Literature and Recommendations for Treatment
- (2008) Neil A. Bayman et al. Clinical Lung Cancer
- Bevacizumab in Non-Small Cell Lung Cancer
- (2008) Francesco Di Costanzo et al. DRUGS
- Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)
- (2008) Ivan Popov et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of lymph nodes with RECIST 1.1
- (2008) L.H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Vinflunine: clinical perspectives of an emerging anticancer agent
- (2008) Adrian Yun-San Yip et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Bevacizumab for the treatment of advanced non-small-cell lung cancer
- (2008) Christian Manegold Expert Review of Anticancer Therapy
- Docetaxel in the treatment of advanced non-small-cell lung cancer
- (2008) Emmanouel Saloustros et al. Expert Review of Anticancer Therapy
- Gene expression profiling of non-small-cell lung cancer
- (2008) Ludovic Lacroix et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Progression-free survival as a surrogate endpoint in advanced breast cancer
- (2008) Rebecca A. Miksad et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
- (2008) Hansjochen Wilke et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- (2008) Tomasz Burzykowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
- (2008) Robert J. Paridaens et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
- (2008) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Biological Agents in Non-small Cell Lung Cancer: A Review of Recent Advances and Clinical Results with a Focus on Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor
- (2008) Karen Kelly et al. Journal of Thoracic Oncology
- Targeting Angiogenesis in the Treatment of Lung Cancer
- (2008) Paul Wheatley-Price et al. Journal of Thoracic Oncology
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
- (2008) R. S. Herbst et al. ONCOLOGIST
- Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
- (2008) S. Ramalingam et al. ONCOLOGIST
- Targeted Therapy in Advanced Non-Small-Cell Lung Cancer
- (2008) Scott Gettinger SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Individual- and trial-level surrogacy in colorectal cancer
- (2008) Marc Buyse et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Neoadjuvant Therapy for Resectable Non–Small Cell Lung Cancer with Mediastinal Lymph Node Involvement
- (2008) Brandon H. Tieu et al. Thoracic Surgery Clinics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now